Chang Hun Lee

Chang Hun Lee

Auto-generated profile, based on publicly available information

Chang Hun Lee

Department of Pathology, Pusan National University School of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MPMin Gyoung Pak
Min Gyoung Pak
DSDong Hoon Shin
Dong Hoon Shin
CLChang Hun Lee
Chang Hun Lee
MLMin Ki Lee
Min Ki Lee
Background: The tumor-associated calcium signal transducer (TACSTD) genes, originally designated epithelial cell adhesion molecule (EpCAM) and TROP2, represent true oncogenes. Little is known about EpCAM and TROP2 gene expression in non-small cell lung carcinoma (NSCLC). This study evaluated EpCAM and TROP2 protein expression and clinicopathologic significance in cases of NSCLC. Methods: Tissue microarray blocks acquired from 164 cases of NSCLC, including 100 cases of adenocarcinoma (AdC) and 64 of squamous cell carcinoma (SCC), were examined by immunohistochemical staining for EpCAM, and TROP2. The results were correlated with clinicopathologic data. Results: EpCAM and TROP2 were significantly overexpressed in SCC than in AdC (P < 0.01). In AdC, EpCAM overexpression was closely related to sex, histologic grade, pathologic T stage, pathologic N stage, and TNM stage, and TROP2 overexpression was only related to histologic grade (P < 0.05, respectively). In SCC, correlations were evident between EpCAM overexpression and TNM stage (P = 0.01), and between TROP2 overexpression and pathologic T stage (P = 0.02). EpCAM overexpression showed no significance with overall survival in AdC and SCC patients. However, TROP2 overexpression in AdC had a positive influence on overall survival (P = 0.02) and disease-free survival (P = 0.03). In particular, AdC patients with stage II or III showed better overall survival (P = 0.05) and disease-free survival (P = 0.04). Conclusions: While EpCAM and TROP2 show weak and non-complete membranous staining in normal bronchial epithelium and pneumocyte, their complete membranous expression in carcinoma suggests their role in carcinogenesis. EpCAM and TROP2 were more frequently overexpressed in SCC. EpCAM overexpression had no prognostic value in this study, but TROP2 overexpression showed better survival in AdC patients and might be a better prognostic marker in advanced stage AdC.

1 October 2009 in Lung
Verified
Journal Article
Closed access
PDF file
SKSang Hyun Kim
Sang Hyun Kim
SLSangyull Lee
Sangyull Lee
CLChang Hun Lee
Chang Hun Lee
MLMin Ki Lee
Min Ki Lee
YKYoung Dae Kim
Young Dae Kim
MSMee Young Sol
Mee Young Sol

20 April 2015 in Histopathology
Verified
Journal Article
Closed access
PDF file
YKYoung K Kim
Young K Kim
DSDong H Shin
Dong H Shin
KKKyung B Kim
Kyung B Kim
NSNari Shin
Nari Shin
WPWon Y Park
Won Y Park
MKMi H Kim
Mi H Kim

1 January 2003 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
CLChang Hun Lee
Chang Hun Lee
MLMin Ki Lee
Min Ki Lee
CKChi Duk Kang
Chi Duk Kang
YKYoung Dae Kim
Young Dae Kim
DPDo Youn Park
Do Youn Park
KSKang Suek Suh
Kang Suek Suh
Lee CH, et al. J Korean Med Sci. 2003 Apr;18(2):196-203. https://doi.org/10.3346/jkms.2003.18.2.196

12 April 2017 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JLJung Hee Lee
Jung Hee Lee
DSDong Hoon Shin
Dong Hoon Shin
WPWon Young Park
Won Young Park
NSNari Shin
Nari Shin
AKAhrong Kim
Ahrong Kim
MSMee Young Sol
Mee Young Sol
Isocitrate dehydrogenase 1 (IDH1) mutation is common in low-grade glioma (approximately 80%) and acute myeloid leukemia (approximately 10%). Other than brain tumor or hematologic malignancies, intrahepatic cholangiocarcinoma (iCC) is a well-known solid tumor with IDH1 mutation (6.8–20%). Histologically, poor differentiation and clear cell change are associated with IDH1 mutation in iCC. Since hepatocellular carcinoma (HCC) shares histologic features with iCC, some specific subtypes of HCC might show a higher IDH1 mutation rate than reported before (0.5–1.5%). Forty-six cases of iCC and 48 cases of HCC (including 20 cases of clear cell type and 13 cases of pseudoglandular pattern) were tested for IDH1 mutation by pyrosequencing. Three cases in iCC (6.5%) and five cases in HCC (10.4%) had IDH1 mutation, all of which were Arg132Cys. IDH1 mutant HCCs were all clear cell type. Although the IDH1 mutation rate between iCC and HCC demonstrated no significant difference, clear cell HCC revealed statistically increased mutation rate compared to that of HCC without clear cell change (P = 0.009). Presence of IDH1 mutation was related with poor survival in clear cell HCC patients (P = 0.004). Clear cell HCC showed higher frequency of IDH1 mutation rate than other variants of HCC. This result consolidates the assumption that morphological features of tumors reflect molecular alterations.

12 July 2015 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
MPMin Gyoung Pak
Min Gyoung Pak
CLChang-Hun Lee
Chang-Hun Lee
WLWoo-Jeong Lee
Woo-Jeong Lee
DSDong-Hoon Shin
Dong-Hoon Shin
MRMee-Sook Roh
Mee-Sook Roh
Lung cancer is the leading cause of cancer mortality, despite development of therapeutic strategies. Altered expression of microRNAs(miRNAs) in human malignancies have been well recognized as diagnostic and prognostic indicators, including lung cancer. This study aims to delineate the clinicopathologic significance of three unique miRNAs in adenocarcinoma according to major sensitive EGFR mutation status. One-hundred and three formalin-fixed paraffin-embedded (FFPE) tissues were collected from lung adenocarcinoma patients who underwent surgery and epidermal growth factor receptor (EGFR) mutation study. The samples were divided into three groups which include EGFR mutation in exons 19 and 21 and wild type. Some representative cases from each group were profiled using commercial miRNA microarray plates. Three significant miRNAs were selected and they were validated by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), using collective cases of FFPE samples. We identified three microRNAs (miR-34c, miR-183, and miR-210) which showed significantly altered expression in all groups of lung adenocarcinoma by microarray study. Compared to normal control lung tissue, down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups (p < 0.05 for each). We validated the expression of three miRNAs by qRT-PCR. Expression levels of miR-34c, miR-183, and miR-210 were significantly different between normal control group and cancer groups (p = 0.034, <0.000, and 0.036, respectively). Moreover, expression level of miR-183 was significantly higher in EGFR mutation groups than wild type group (p = 0.028). Higher expression levels of three miRNAs were positively related to poor tumor differentiation. Increased expression of miR-183 was positively associated with lymphovascular invasion (p = 0.037). Aberrant expression of miR-210 was independently associated with T stage (p = 0.019), and TNM stage (p = 0.007). However, there was noted a limited statistical significance. In EGFR exon 19 mutation group, miR-34c high expression group showed poor overall survival than low expression one by univariate Kaplan-Meier method. (p = 0.035). Here, we show that miR-34c may act as a potential tumor suppressor gene and miR-183 and miR-210 have a potential oncogenic role in pulmonary adenocarcinoma. This study also suggests different miRNA expression between EGFR mutation group and wild type group. Consequently, further studies of the biology of miRNAs may lead to diagnostic and prognostic biomarkers in pulmonary adenocarcinoma.